InvestorsHub Logo
Followers 43
Posts 5908
Boards Moderated 1
Alias Born 11/27/2009

Re: None

Monday, 10/02/2023 11:16:43 AM

Monday, October 02, 2023 11:16:43 AM

Post# of 671
$YECO EV Biologics Updates on Funding and Sales

TAMPA, FL / ACCESSWIRE / October 2, 2023 / EV Biologics Corp, (OTC Pink:YECO), today announced that it has closed a $500,000 interest-free loan from a related party.

This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process. The funds will be also used for comprehensive product analysis by several leading independent laboratories.

The Company has already begun sales of some of its regenerative products through its agents in Asia for pre-clinical use and testing and expects to start sales in South America by November this year. The Company filed an application for a trademark under the product name: EcoCura with the U.S. Trademark Office on September 22, 2023.

As reported in the August 7, 2023 press release, the Company is moving with audits and the filing with FINRA for the name and symbol change. Furthermore, our Director of Corporate Finance, William Bossung is heading up our efforts to re-apply to up-list to Nasdaq.

CEO, Daniel Mckinney, said "Our audacious goal is to revolutionize modern medicine by harvesting the healing power naturally produced by living cells to develop versatile therapeutics and enable safe and effective treatment of a wide range of clinical conditions for better health & longevity.

To minimize capital requirements, Excyte is developing essential product and process technologies in parallel with its primary therapeutic development pathway through collaboration with best-in-class commercial partners. Intellectual property, patents, proprietary process and product development will be held by Excyte in support of EV Biologics.